Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Revenue (2020 - 2024)

Goldenwell Biotech (GWLL) has disclosed Revenue for 5 consecutive years, with -$158.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Revenue fell 160.77% year-over-year to -$158.0, compared with a TTM value of -$158.0 through Sep 2025, down 128.37%, and an annual FY2024 reading of $139.0, down 92.43% over the prior year.
  • Revenue was -$158.0 for Q4 2024 at Goldenwell Biotech, down from $297.0 in the prior quarter.
  • Across five years, Revenue topped out at $43690.0 in Q3 2022 and bottomed at -$4110.0 in Q4 2022.
  • Average Revenue over 5 years is $4438.6, with a median of $389.5 recorded in 2022.
  • The sharpest move saw Revenue soared 22020.0% in 2021, then tumbled 252.5% in 2022.
  • Year by year, Revenue stood at $5.0 in 2020, then skyrocketed by 53800.0% to $2695.0 in 2021, then crashed by 252.5% to -$4110.0 in 2022, then skyrocketed by 106.33% to $260.0 in 2023, then tumbled by 160.77% to -$158.0 in 2024.
  • Business Quant data shows Revenue for GWLL at -$158.0 in Q4 2024, $297.0 in Q2 2024, and $260.0 in Q4 2023.